191 results on '"Pierce, Evangeline"'
Search Results
2. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
3. The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
4. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
5. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
6. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
7. Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
8. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis
9. Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale
10. Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
11. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
12. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
13. Impact of atopic dermatitis lesion locations and extent on patient burden: A real‐world study.
14. A Qualitative Analysis of Provider Notes of Atopic Dermatitis-Related Visits Using Natural Language Processing Methods
15. Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
16. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
17. Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral
18. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
19. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16- week results from three randomized phase 3 clinical trials.
20. Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial.
21. 680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.
22. 627 - A checklist to aid in identifying patients with atopic dermatitis who are candidates for systemic therapy.
23. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
24. Improvement in health-related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials.
25. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
26. 730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity.
27. 726 - Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis.
28. 708 - Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years.
29. 626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age.
30. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
31. Long‐term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate‐to‐severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE‐AD7
32. Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review.
33. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry.
34. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
35. Burden of adult atopic dermatitis and unmet needs with existing therapies.
36. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
37. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
38. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes.
39. 52100 Improvement of itch and sleep disturbance symptoms in patients with moderate-to-severe atopic dermatitis treated with lebrikizumab is maintained over 52 weeks as measured weekly with POEM.
40. 53788 The patient-reported impact of flares on quality of life in pediatric and adolescent patients with moderate-to-severe atopic dermatitis: a real-world study in the United States and Europe.
41. 51219 Lebrikizumab Monotherapy Maintained Improvement of Itch and Sleep-Loss Due to Itch After Two Years in Patients with Moderate-to-Severe Atopic Dermatitis.
42. 50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis.
43. 51075 HADS anxiety and depression scores improved in Japanese patients with moderate-to-severe atopic dermatitis following lebrikizumab treatment: 16-week results from a randomized, double-blind, placebo-controlled phase 3 trial (ADhere-J).
44. 594 - United States prevalence of atopic dermatitis in adults and pediatrics by race and ethnicity.
45. 382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab.
46. 42136 Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
47. 42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy
48. 43072 Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
49. 42928 The patient-reported impact of itch and sleep interference on pediatric and adolescent patients with moderate and severe atopic dermatitis: a real-world study in the United States and Europe
50. 42917 Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.